• 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-02
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • Michailidou K Beesley J Lindstrom S et al


    6. Michailidou K, Beesley J, Lindstrom S, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 2015; 47:373-80.
    7. Peng S, Lü B, Ruan W, Zhu Y, Sheng H, Lai M. Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies. Breast Cancer Res Treat 2011; 12:309-24.
    12. Sapkota Y, Mackey JR, Lai R, et al. Assessing SNP-SNP interactions among DNA repair, modification and metabolism related pathway genes in breast cancer sus-ceptibility. PLoS One 2013; 8:e64896.
    15. Gonzalez-Suarez E, Jacob A, Jones J, et al. RANK ligand mediates progestin induced mammary epithelial proliferation and carcinogenesis. Nature 2010; 468:103-7. 16. Tan W, Zhang W, Strasner A, et al. Tumour infiltrating regulatory T GSK'872 stim-ulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470:548-53.
    18. Libreros S, Garcia-Areas R, Iragavarapu-Charyulu V. CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunol Res 2013; 57:99-105.
    20. Lopes N, Paredes J, Costa JL, Ylstra B, Schmitt F. Vitamin D and the mammary gland: a review on its role in normal development and breast cancer. Breast Cancer Res 2012; 14:211.
    21. McCullough ML, Stevens VL, Diver WR, et al. Vitamin D pathway gene poly-morphisms, diet, and risk of postmenopausal breast cancer: a nested caseecontrol study. Breast Cancer Res 2007; 9:R9.
    23. Omar HS, Shaker OG, Nassar YH, Marzouk SA, ElMarzouky MS. The associa-tion between RANKL and osteoprotegerin gene polymorphisms with breast cancer. Mol Cell Biochem 2015; 403:219-29.
    24. Ney JT, Juhasz-Boess I, Gruenhage F, et al. Genetic polymorphism of the OPG gene associated with breast cancer. BMC Cancer 2013; 13:40.
    26. Sinotte M, Rousseau F, Ayotte P, et al. Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two caseecontrol studies within French Canadian population. Endocr Relat Cancer 2008; 15:975-83. 27. Tang C, Chen N, Wu M, et al. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 2009; 117:391-9.
    28. Shahabi A, Alipour M, Safiri H, et al. Vitamin D receptor gene polymorphism: association with susceptibility to early-onset breast cancer in Iranian, BRCA1/2-mutation carrier and non-carrier patients. Pathol Oncol Res 2018; 24:601-7.
    29. Rashid MU, Muzaffar M, Khan FA, et al. Association between the BsmI poly-morphism in the vitamin D receptor gene and breast cancer risk: results from a Pakistani caseecontrol study. PLoS One 2015; 10:e0141562.
    30. Zhao HY, Liu JM, Ning G, et al. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. Osteoporos Int 2005; 16:1519-24. 
    31. Arko B, Preelj J, Komel R, Kocijani A, Hudler P, Marc J. Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab 2002; 87:4080-4.
    34. Arai H, Miyamoto KI, Taketani Y, et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japan women. J Bone Miner Res 1997; 12:915-21.
    36. Luo XY, Yang MH, Wu FX, et al. Vitamin D receptor gene BsmI polymorphism B allele, but not BB genotype, is associated with systemic lupus erythematosus in a Han Chinese population. Lupus 2012; 21:53-9.
    37. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using David Bioinformatics Resources. Nature Protoc 2009; 4:44-57.